Bridgebio Pharma, Inc. · NASDAQ:BBIO

Kumar Neil sold 60,000 Bridgebio Pharma, Inc. shares (Form 4)

Traded Apr 9 to Apr 10, 2026 · Filed Apr 13, 2026

From Apr 9 to Apr 10, 2026, Kumar Neil (Director, Chief Executive Officer) sold 60,000 Bridgebio Pharma, Inc. shares at an average US$74.61 for US$4.48M under a trading plan, leaving 4,398,447 shares. Filed Apr 13, 2026 (Form 4).

Sold
60,000 shares
Price
US$74.61 average (US$73.64 to US$75.55)
Value
US$4.48M
Holding after
4,398,447 shares (held indirectly)
Trading plan
Yes (Made under a plan set in advance)
Role
Director, Chief Executive Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Apr 9, 2026Common StockSale7,200US$73.64628,486Indirect
Apr 9, 2026Common StockSale5,300US$74.60623,186Indirect
Apr 9, 2026Common StockSale7,500US$75.55615,686Indirect
Apr 9, 2026Common StockSale7,072US$73.644,431,375Indirect
Apr 9, 2026Common StockSale5,128US$74.574,426,247Indirect
Apr 9, 2026Common StockSale7,800US$75.534,418,447Indirect
Apr 10, 2026Common StockSale20,000US$74.604,398,447Indirect

Source

View original at SEC

Related